Pockets lined with $300,000 in investment capital, Ann Arbor-based SensiGen, LLC, is expanding. The biotech company will add two jobs in the short-term and another dozen over the next year, President and CEO Shawn Marcell (CQ) says, thanks to the award from Pennsylvania-based Delaware Crossing Investors Group.
All positions, Marcell says, are highly-skilled scientific jobs.
The investment was finalized last week. SensiGen, which has an auxiliary office in Pennsylvania, is a development stage biotechnology company focused on gene-based molecular diagnostics, according to the company's Web site, with technology geared toward early detection of disease.
The Ann Arbor facility is the company's main campus, Marcell says, and is where all of SensiGen's research and development is sited.
The Delaware group is the latest addition to the SensiGen bankroll - the company has also received a $2.6 million grant from the Michigan Economic Development Corporation in 2005 and $250,000 from Ann Arbor SPARK earlier this year, Marcell says.
Source: Shawn Marcell, SensiGen, LLC
Writer: Nancy Kaffer
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.